Drug firm Ajanta Pharma today said its standalone net profit rose by 17.91 per cent to Rs 11.85 crore for the quarter ended September 30. The company had posted a net profit of Rs 10.05 crore for the quarter ended September 30, 2010, Ajanta Pharma said in a filing to the Bombay Stock Exchange.
Its standalone net sales for the second quarter of this fiscal stood at Rs 135.12 crore against Rs 112.50 crore for the corresponding period last fiscal.
The company said it has received one more product approval from US health regulator in the July-September period this fiscal.
“We have received one more product (Abbreviated New Drug Application) approval from USA this quarter. With this approval, Ajanta Pharma has two approved products for the USA,” the Ajanta Pharma MD, Mr Yogesh Agrawal, said.
Shares of Ajanta Pharma were today trading at Rs 324 in the afternoon trade on BSE, up 0.40 per cent from its previous close.